Epizyme Analysis

Epizyme Stock Analysis Notes

About 90.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.0. Some equities with similar Price to Book (P/B) outperform the market in the long run. Epizyme recorded a loss per share of 2.3. The entity had not issued any dividends in recent years. Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Epizyme operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 250 people. To learn more about Epizyme call Robert Bazemore at 617 229-5872 or check out www.epizyme.com.

Epizyme Investment Alerts

Epizyme Thematic Classifications

Epizyme Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 152.73 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Epizyme's market, we take the total number of its shares issued and multiply it by Epizyme's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Epizyme Predictive Daily Indicators

Stock analysis is the technique used by a trader or investor to examine and evaluate how Epizyme prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Epizyme shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Epizyme. By using and applying Epizyme Stock analysis, traders can create a robust methodology for identifying Epizyme entry and exit points for their positions.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Epizyme information on this page should be used as a complementary analysis to other Epizyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

If you are still planning to invest in Epizyme check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Epizyme's history and understand the potential risks before investing.